Wall Street's M&A Chatter From March 6

The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday, March 6, 2017.

Vertex to Acquire CTP-656 from Concert Pharmaceuticals for $160M Cash, Potential $90M in Milestones

The Deal:

Concert Pharmaceuticals, Inc. CNCE announced it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals, Inc. VRTX under which Vertex will acquire investigational cystic fibrosis transmembrane conductance regulator CTP-656 for $160 million in cash for all worldwide development and commercialization rights, plus up to an additional $90 million in milestones based on U.S. regulatory approval and reimbursement in the UK, Germany or France.

Vertex will also acquire rights to all of Concert's other CF research and preclinical programs.

Concert Pharmaceuticals rose 62 percent on Monday to close at $15.64.

Cameco Explores Sale of U.S. Uranium Mines

The CEO Comment:

Cameco Corp CCJ is considering selling its U.S. production facilities, according to its CEO Tim Gitzel in an interview with Reuters. Cameco is in the early stages of evaluating the sale of its uranium mines in Wyoming and Nebraska, Gitzel said, but he is seeking clarity on President Trump's plans for nuclear power.

Cameco closed at $10.89, up $0.02.

Thinkbox Software Company News - Thinkblog - Thinkbox Software

The Deal:

Thinkbox Software announced it was acquired by Amazon AMZN and will be working with Amazon Web Services. Terms were not dislcosed.

Amazon closed at $846.61 on Monday, down $1.60.